Cancer API Market Research Report Information by Drug Type (Innovative Oncology API, And Generic Oncology API), By Manufacturer Type (Captive Manufacturer, Merchant Manufacturer), By Type Of Synthesis (Synthetic Oncology Apis, And Biotech Oncology API), By Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Liver Cancer, Cervical Cancer, And Others), and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING DEMAND FOR NEWLY DEVELOPED SMALL MOLECULE DRUGS

4.2.2 RISING PREVALENCE OF CANCER

4.2.3 GROWING TREND OF PHARMACEUTICAL OUTSOURCING

4.3 RESTRAINTS

4.3.1 STRINGENT REGULATORY REQUIREMENTS

4.4 OPPORTUNITY

4.4.1 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D & DESIGNING

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE GLOBAL CANCER API MARKET

5.3.1 IMPACT ON SUPPLY CHAIN

5.3.2 IMPACT ON PRODUCTION

5.3.3 IMPACT ON REGIONS

5.3.4 IMPACT ON DEMAND-SUPPLY GAP ANALYSIS

5.3.5 IMPACT ON PRICING

6 GLOBAL CANCER API MARKET, BY DRUG TYPE

6.1 OVERVIEW

6.2 INNOVATIVE ONCOLOGY APIS

6.3 GENERIC ONCOLOGY APIS

7 GLOBAL CANCER API MARKET, BY MANUFACTURER TYPE

7.1 OVERVIEW

7.2 CAPTIVE MANUFACTURERS

7.3 MERCHANT MANUFACTURERS

8 GLOBAL CANCER API MARKET, BY TYPE OF SYNTHESIS

8.1 OVERVIEW

8.2 SYNTHETIC ONCOLOGY APIS

8.3 BIOTECH ONCOLOGY APIS

9 GLOBAL CANCER API MARKET, BY INDICATION

9.1 OVERVIEW

9.2 LUNG CANCER

9.3 BREAST CANCER

9.4 COLORECTAL CANCER

9.5 PROSTATE CANCER

9.6 STOMACH CANCER

9.7 LIVER CANCER

9.8 CERVICAL CANCER

9.9 OTHERS

10 GLOBAL CANCER API MARKET, BY REGION

10.1 OVERVIEW

10.2 NORTH AMERICA

10.2.1 US

10.2.2 CANADA

10.3 EUROPE

10.3.1 GERMANY

10.3.2 FRANCE

10.3.3 UK

10.3.4 ITALY

10.3.5 SPAIN

10.3.6 REST OF EUROPE

10.4 ASIA-PACIFIC

10.4.1 CHINA

10.4.2 INDIA

10.4.3 JAPAN

10.4.4 AUSTRALIA

10.4.5 SOUTH KOREA

10.4.6 REST OF ASIA-PACIFIC

10.5 REST OF THE WORLD

10.5.1 MIDDLE EAST

10.5.2 AFRICA

10.5.3 LATIN AMERICA

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW

11.2 COMPETITIVE BENCHMARKING

11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL CANCER API MARKET

11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL CANCER API MARKET

11.5 KEY DEVELOPMENT ANALYSIS

11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

11.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL

11.6.2 MERGER/ACQUISITION

11.6.3 PARTNERSHIP/ AGREEMENT/COLLABORATION

11.6.4 EXPANSION/ INVESTMENT

11.7 MAJOR PLAYERS SALES ANALYSIS

11.7.1 SALES

11.8 MAJOR PLAYERS R&D ANALYSIS

12 COMPANY PROFILES

12.1 AVRA LABORATORIES PVT LTD

12.1.1 COMPANY OVERVIEW

12.1.2 FINANCIAL OVERVIEW

12.1.3 PRODUCTS OFFERED

12.1.4 KEY DEVELOPMENTS

12.1.5 KEY STRATEGIES

12.2 BIOCON

12.2.1 COMPANY OVERVIEW

12.2.2 FINANCIAL OVERVIEW

12.2.3 PRODUCTS OFFERED

12.2.4 KEY DEVELOPMENTS

12.2.5 SWOT ANALYSIS

12.2.6 KEY STRATEGIES

12.3 TEVA PHARMACEUTICAL INDUSTRIES LTD

12.3.1 COMPANY OVERVIEWS

12.3.2 FINANCIAL OVERVIEW

12.3.3 PRODUCTS OFFERED

12.3.4 KEY DEVELOPMENTS

12.3.5 SWOT ANALYSIS

12.3.6 KEY STRATEGIES

12.4 BOCHEM PVT. LTD

12.4.1 COMPANY OVERVIEW

12.4.2 FINANCIAL OVERVIEW

12.4.3 PRODUCTS OFFERED

12.4.4 KEY DEVELOPMENTS

12.4.5 KEY STRATEGIES

12.5 MAC-CHEM PRODUCTS (INDIA) PVT. LTD

12.5.1 COMPANY OVERVIEW

12.5.2 FINANCIAL OVERVIEW

12.5.3 PRODUCTS OFFERED

12.5.4 KEY DEVELOPMENTS

12.5.5 KEY STRATEGIES

12.6 DR. REDDY’S LABORATORIES LTD

12.6.1 COMPANY OVERVIEW

12.6.2 FINANCIAL OVERVIEW

12.6.3 PRODUCTS OFFERED

12.6.4 KEY DEVELOPMENTS

12.6.5 SWOT ANALYSIS

12.6.6 KEY STRATEGIES

12.7 SUN PHARMACEUTICAL INDUSTRIES LIMITED

12.7.1 COMPANY OVERVIEW

12.7.2 FINANCIAL OVERVIEW

12.7.3 PRODUCTS OFFERED

12.7.4 KEY DEVELOPMENTS

12.7.5 SWOT ANALYSIS

12.7.6 KEY STRATEGIES

12.8 BETA DRUGS LIMITED

12.8.1 COMPANY OVERVIEW

12.8.2 FINANCIAL OVERVIEW

12.8.3 PRODUCTS OFFERED

12.8.4 KEY DEVELOPMENTS

12.8.5 SWOT ANALYSIS

12.8.6 KEY STRATEGIES

12.9 AXPLORA

12.9.1 COMPANY OVERVIEW

12.9.2 FINANCIAL OVERVIEW

12.9.3 PRODUCTS OFFERED

12.9.4 KEY DEVELOPMENTS

12.9.5 KEY STRATEGIES

12.10 BULAT PHARMACEUTICAL

12.10.1 COMPANY OVERVIEW

12.10.2 FINANCIAL OVERVIEW

12.10.3 PRODUCTS OFFERED

12.10.4 KEY DEVELOPMENTS

12.10.5 KEY STRATEGIES

13 APPENDIX

13.1 REFERENCES

13.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

TABLE 3 FDA-APPROVED SMALL MOLECULE COMPOUNDS AS DRUGS FOR SOLID CANCERS (2019 - 2021)

TABLE 4 GLOBAL CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 5 GLOBAL CANCER API MARKET, FOR INNOVATIVE ONCOLOGY APIS, BY REGION, 2019–2030 (USD MILLION)

TABLE 6 GLOBAL CANCER API MARKET, FOR GENERIC ONCOLOGY APIS, BY REGION, 2019–2030 (USD MILLION)

TABLE 7 GLOBAL CANCER API MARKET, BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 8 GLOBAL CANCER API MARKET, FOR CAPTIVE MANUFACTURERS, BY REGION, 2019–2030 (USD MILLION)

TABLE 9 GLOBAL CANCER API MARKET, FOR MERCHANT MANUFACTURERS, BY REGION, 2019–2030 (USD MILLION)

TABLE 10 GLOBAL CANCER API MARKET, BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 11 GLOBAL CANCER API MARKET, FOR SYNTHETIC ONCOLOGY APIS, BY REGION, 2019–2030 (USD MILLION)

TABLE 12 GLOBAL CANCER API MARKET, FOR BIOTECH ONCOLOGY APIS, BY REGION, 2019–2030 (USD MILLION)

TABLE 13 GLOBAL CANCER API MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 14 GLOBAL CANCER API MARKET, FOR LUNG CANCER , BY REGION, 2019–2030 (USD MILLION)

TABLE 15 GLOBAL CANCER API MARKET, FOR BREAST CANCER, BY REGION, 2019–2030 (USD MILLION)

TABLE 16 GLOBAL CANCER API MARKET, FOR COLORECTAL CANCER, BY REGION, 2019–2030 (USD MILLION)

TABLE 17 GLOBAL CANCER API MARKET, FOR PROSTATE CANCER, BY REGION, 2019–2030 (USD MILLION)

TABLE 18 GLOBAL CANCER API MARKET, FOR STOMACH CANCER, BY REGION, 2019–2030 (USD MILLION)

TABLE 19 GLOBAL CANCER API MARKET, FOR LIVER CANCER, BY REGION, 2019–2030 (USD MILLION)

TABLE 20 GLOBAL CANCER API MARKET, FOR CERVICAL CANCER, BY REGION, 2019–2030 (USD MILLION)

TABLE 21 GLOBAL CANCER API MARKET, FOR OTHERS, BY REGION, 2019–2030 (USD MILLION)

TABLE 22 GLOBAL: CANCER API MARKET, BY REGION, 2019–2030 (USD MILLION)

TABLE 23 NORTH AMERICA: CANCER API MARKET, BY COUNTRY, 2019–2030 (USD MILLION)

TABLE 24 NORTH AMERICA: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 25 NORTH AMERICA: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 26 NORTH AMERICA: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 27 NORTH AMERICA: CANCER API MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 28 US: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 29 US: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 30 US: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 31 US: CANCER API MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 32 CANADA: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 33 CANADA: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 34 CANADA: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 35 CANADA: CANCER API MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 36 EUROPE: CANCER API MARKET, BY COUNTRY, 2019–2030 (USD MILLION)

TABLE 37 EUROPE: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 38 EUROPE: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 39 EUROPE: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 40 EUROPE: CANCER API MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 41 GERMANY: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 42 GERMANY: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 43 GERMANY: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 44 GERMANY: CANCER API MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 45 FRANCE: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 46 FRANCE: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 47 FRANCE: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 48 FRANCE: CANCER API MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 49 UK: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 50 UK: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 51 UK: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 52 UK: CANCER API MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 53 ITALY: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 54 ITALY: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 55 ITALY: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 56 ITALY: CANCER API MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 57 SPAIN: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 58 SPAIN: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 59 SPAIN: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 60 SPAIN: CANCER API MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 61 REST OF EUROPE: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 62 REST OF EUROPE: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 63 REST OF EUROPE: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 64 REST OF EUROPE: CANCER API MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 65 ASIA-PACIFIC: CANCER API MARKET, BY COUNTRY, 2019–2030 (USD MILLION)

TABLE 66 ASIA-PACIFIC: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 67 ASIA-PACIFIC: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 68 ASIA-PACIFIC: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 69 ASIA-PACIFIC: CANCER API MARKET BY INDICATION, 2019–2030 (USD MILLION)

TABLE 70 CHINA: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 71 CHINA: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 72 CHINA: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 73 CHINA: CANCER API MARKET BY INDICATION, 2019–2030 (USD MILLION)

TABLE 74 INDIA: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 75 INDIA: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 76 INDIA: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 77 INDIA: CANCER API MARKET BY INDICATION, 2019–2030 (USD MILLION)

TABLE 78 JAPAN: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 79 JAPAN: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 80 JAPAN: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 81 JAPAN: CANCER API MARKET BY INDICATION, 2019–2030 (USD MILLION)

TABLE 82 AUSTRALIA: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 83 AUSTRALIA: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 84 AUSTRALIA: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 85 AUSTRALIA: CANCER API MARKET BY INDICATION, 2019–2030 (USD MILLION)

TABLE 86 SOUTH KOREA: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 87 SOUTH KOREA: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 88 SOUTH KOREA: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 89 SOUTH KOREA: CANCER API MARKET BY INDICATION, 2019–2030 (USD MILLION)

TABLE 90 REST OF ASIA-PACIFIC: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 91 REST OF ASIA-PACIFIC: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 92 REST OF ASIA-PACIFIC: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 93 REST OF ASIA-PACIFIC: CANCER API MARKET BY INDICATION, 2019–2030 (USD MILLION)

TABLE 94 REST OT THE WORLD: CANCER API MARKET, BY REGION, 2019–2030 (USD MILLION)

TABLE 95 REST OF THE WORLD: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 96 REST OF THE WORLD: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 97 REST OF THE WORLD: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 98 REST OF THE WORLD: CANCER API MARKET BY INDICATION, 2019–2030 (USD MILLION)

TABLE 99 MIDDLE EAST: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 100 MIDDLE EAST: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 101 MIDDLE EAST: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 102 MIDDLE EAST: CANCER API MARKET BY INDICATION, 2019–2030 (USD MILLION)

TABLE 103 AFRICA: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 104 AFRICA: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 105 AFRICA: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 106 AFRICA: CANCER API MARKET BY INDICATION, 2019–2030 (USD MILLION)

TABLE 107 LATIN AMERICA: CANCER API MARKET, BY DRUG TYPE, 2019–2030 (USD MILLION)

TABLE 108 LATIN AMERICA: CANCER API MARKET BY MANUFACTURER TYPE, 2019–2030 (USD MILLION)

TABLE 109 LATIN AMERICA: CANCER API MARKET, BY TYPE OF SYNTHESIS, 2019–2030 (USD MILLION)

TABLE 110 LATIN AMERICA: CANCER API MARKET BY INDICATION, 2019–2030 (USD MILLION)

TABLE 111 MAJOR PLAYERS IN THE GLOBAL CANCER API MARKET

TABLE 112 MOST ACTIVE PLAYER IN THE GLOBAL CANCER API MARKET

TABLE 113 PRODUCT LAUNCH/PRODUCT APPROVAL

TABLE 114 MERGER/ACQUISITION

TABLE 115 PARTNERSHIP/ AGREEMENT/COLLABORATION

TABLE 116 EXPANSION/ INVESTMENT

TABLE 117 AVRA LABORATORIES PVT LTD: PRODUCTS OFFERED

TABLE 118 AVRA LABORATORIES PVT LTD: KEY DEVELOPMENTS

TABLE 119 BIOCON: PRODUCTS OFFERED

TABLE 120 BIOCON: KEY DEVELOPMENTS

TABLE 121 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED

TABLE 122 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENT

TABLE 123 BOCHEM PVT. LTD.: PRODUCTS OFFERED

TABLE 124 MAC-CHEM PRODUCTS (INDIA) PVT. LTD: PRODUCTS OFFERED

TABLE 125 DR. REDDY’S LABORATORIES LTD: PRODUCTS OFFERED

TABLE 126 DR. REDDY'S LABORATORIES: KEY DEVELOPMENTS

TABLE 127 SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCTS OFFERED

TABLE 128 SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY DEVELOPMENTS

TABLE 129 BETA DRUGS LIMITED: PRODUCTS/SERVICES OFFERED

TABLE 130 BETA DRUGS LIMITED: KEY DEVELOPMENTS

TABLE 131 AXPLORA: PRODUCTS OFFERED

TABLE 132 BULAT PHARMACEUTICAL: PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS

FIGURE 2 GLOBAL CANCER API MARKET

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 4 MARKET DYNAMICS: GLOBAL CANCER API MARKET

FIGURE 5 DRIVER IMPACT ANALYSIS

FIGURE 6 RESTRAINT IMPACT ANALYSIS

FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL CANCER API MARKET

FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL CANCER API MARKET

FIGURE 9 GLOBAL CANCER API MARKET, DRUG TYPE SEGMENT ATTRACTIVENESS, 2019-2030 (USD MILLION)

FIGURE 10 GLOBAL CANCER API MARKET, BY DRUG TYPE, 2022 & 2030 (USD MILLION)

FIGURE 11 GLOBAL CANCER API MARKET, MANUFACTURER TYPE SEGMENT ATTRACTIVENESS, 2019-2030 (USD MILLION)

FIGURE 12 GLOBAL CANCER API MARKET, BY MANUFACTURER TYPE, 2022 & 2030 (USD MILLION)

FIGURE 13 GLOBAL CANCER API MARKET, TYPE OF SYNTHESIS SEGMENT ATTRACTIVENESS, 2019-2030 (USD MILLION)

FIGURE 14 GLOBAL CANCER API MARKET, BY TYPE OF SYNTHESIS, 2022 & 2030 (USD MILLION)

FIGURE 15 NUMBER OF NEW CASES IN 2020, BOTH SEXES, ALL AGES, GLOBALLY

FIGURE 16 GLOBAL CANCER API MARKET, TYPE OF SYNTHESIS SEGMENT ATTRACTIVENESS, 2019-2030 (USD MILLION)

FIGURE 17 GLOBAL: CANCER API MARKET, BY REGION, 2022 & 2030

FIGURE 18 GLOBAL: CANCER API MARKET SHARE (%), BY REGION, 2022

FIGURE 19 NORTH AMERICA MARKET ANALYSIS: CANCER API MARKET, 2019-2030 (USD MILLION)

FIGURE 20 NORTH AMERICA: CANCER API MARKET, BY COUNTRY, 2022 & 2030

FIGURE 21 NORTH AMERICA: CANCER API MARKET SHARE (%), BY COUNTRY, 2022

FIGURE 22 EUROPE MARKET ANALYSIS: CANCER API MARKET, 2019-2030 (USD MILLION)

FIGURE 23 EUROPE: CANCER API MARKET, BY COUNTRY, 2022 & 2030

FIGURE 24 EUROPE: CANCER API MARKET SHARE (%), BY COUNTRY, 2022

FIGURE 25 ASIA-PACIFIC MARKET ANALYSIS: CANCER API MARKET, 2019-2030 (USD MILLION)

FIGURE 26 ASIA-PACIFIC: CANCER API MARKET, BY COUNTRY, 2022 & 2030 (USD MILLION)

FIGURE 27 ASIA-PACIFIC: CANCER API MARKET SHARE (%), BY COUNTRY, 2022

FIGURE 28 REST OF THE WORLD MARKET ANALYSIS: CANCER API MARKET, 2019-2030 (USD MILLION)

FIGURE 29 REST OT THE WORLD: CANCER API MARKET, BY REGION, 2022 & 2030 (USD MILLION)

FIGURE 30 REST OT THE WORLD: CANCER API MARKET SHARE (%), BY REGION, 2022

FIGURE 31 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 32 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL CANCER API MARKET

FIGURE 33 GLOBAL CANCER API MARKET: COMPETITIVE LANDSCAPE

FIGURE 34 MAJOR PLAYERS SALES, 2022

FIGURE 35 MAJOR PLAYER R&D EXPENDITURE, 2022

FIGURE 36 BIOCON: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 37 BIOCON: SWOT ANALYSIS

FIGURE 38 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 39 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS

FIGURE 40 DR. REDDY’S LABORATORIES LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 41 DR. REDDY’S LABORATORIES LTD: SWOT ANALYSIS

FIGURE 42 SUN PHARMACEUTICAL INDUSTRIES LIMITED: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 43 SUN PHARMACEUTICAL INDUSTRIES LIMITED: SWOT ANALYSIS

FIGURE 44 BETA DRUGS LIMITED: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 45 BETA DRUGS LIMITED: SWOT ANALYSIS